Publique en esta revista
Información de la revista
Vol. 5. Núm. D.
Síndrome metabólico: Retos y esperanzas
Páginas 38D-45D (Octubre 2005)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 5. Núm. D.
Síndrome metabólico: Retos y esperanzas
Páginas 38D-45D (Octubre 2005)
Síndrome metabólico: retos y esperanzas
DOI: 10.1016/S1131-3587(05)74119-4
Acceso a texto completo
Hipertensión arterial y síndrome metabólico
Hypertension and Metabolic Syndrome
Visitas
...
Alberto Cordero??
Autor para correspondencia
acordero@unav.es

Correspondencia: Dr. A. Cordero. Departamento de Cardiología. Clínica Universitaria de Navarra. Avda. Pío XII, 36. 31080 Pamplona. Navarra. España.
, José Moreno, Eduardo Alegría
Departamento de Cardiología. Clínica Universitaria de Navarra. Pamplona. Navarra. España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

Las interrelaciones entre la hipertensión arterial y el síndrome metabólico obedecen a nexos fisiopatológicos comunes y tienen importantes implicaciones terapéuticas y pronósticas. La obesidad, la resistencia insulínica y las alteraciones de la función renal se encuentran en el centro del sustrato fisiopatológico y deben ser el objetivo al que dirigir todas las estrategias preventivas y terapéuticas.

Palabras clave:
Hipertensión arterial
Resistencia insulínica
Obesidad
Síndrome metabólico
Abreviaturas:
DM
HTA
PA
SM

The relationship between hypertension and metabolic syndrome is based on are common pathophysiologic factors. This has important therapeutic and prognostic implications. Obesity, insulin resistance, and renal dysfunction form the central core of the pathophysiologic substrate. They must be the main targets of preventive and therapeutic strategies.

Key words:
Hypertension
Insulin resistance
Obesity
Metabolic syndrome
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, et al.
Effect of potentially modificable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
[2.]
H. Tunstall-Pedoe, D. Vanuzzo, M. Hobbs, M. Mähönen, Z. Cepaitis, K. Kuulasmaa, et al.
Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations.
Lancet, 355 (2000), pp. 688-700
[3.]
J.R. González Juanatey, E. Alegría, J.V. Lozano, J.L. Llisteri, J.M. García, I. González.
Impacto de la hipertensión en la cardiopatías en España. Estudio CARDIOTENS 1999.
Rev Esp Cardiol, 54 (2001), pp. 139-149
[4.]
G.M. Reaven.
Role of insulin resistance in human disease.
Diabetes, 37 (1988), pp. 1595-1607
[5.]
S.M. Grundy, B. Hansen, S.C. Smith, J.I. Cleeman, R.A. Kahn, for conference participants American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association.
Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/ American Diabetes Association conference on scientific issues related to management.
Circulation, 109 (2004), pp. 551-556
[6.]
National Cholesterol Education Program (NCEP) Expert Panel on Detection, E.valuation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III final report.
Circulation, 106 (2002), pp. 3143-3421
[7.]
A.V. Chobanian, G.R. Bakris, H.F. Black, W.C. Cushman, L.A. Green, J.L. Izzo, for the National Heart, Lung and Blood institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee, et al.
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
JAMA, 289 (2003), pp. 2560-2572
[8.]
G.M. Reaven, H. Lithell, L. Landsberg.
Hypertension and associated metabolic abnormalities- the role of insulin resistance and the sympathoadrenal system.
N Engl J Med, 334 (1996), pp. 374-381
[9.]
C.M. Alexander, P.B. Landsman, S.M. Teutsch, S.M. Haffner.
NECPDefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.
Diabetes, 52 (2003), pp. 1210-1214
[10.]
M.K. Rutter, J.B. Meigs, L.M. Sullivan, R.B. D’Agostino, P.W. Wilson.
C-Reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study.
Circulation, 110 (2004), pp. 380-385
[11.]
N. Sattar, A. Gaw, O. Scherbakova, I. Ford, D.S. O’Reilly, S.M. Haffner, et al.
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Circulation, 108 (2003), pp. 414-419
[12.]
P.M. Ridker, J.E. Buring, N.R. Cook, N. Rifai.
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: a 8-year follow-up of 14,719 initially healthy American women.
Circulation, 107 (2003), pp. 391-397
[13.]
G. Schillaci, M. Pirro, G. Vaudo, F. Gemelli, S. Marchesi, E. Porcellati, et al.
Prognostic value of the metabolic syndrome in essential hypertension.
J Am Coll Cardiol, 43 (2004), pp. 1817-1822
[14.]
J.F. Ascaso, P. Romero, J.T. Real, R.I. Lorente, J. Martínez-Valls, R. Carmena.
Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population.
Eur J Intern Med, 14 (2003), pp. 101-106
[15.]
K.L. Cheal, F. Abbasi, C. Lamendola, T. McLaughlin, G.M. Reaven, E.S. Ford.
Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome.
Diabetes, 53 (2004), pp. 1195-1200
[16.]
P. Guallar-Castellón, J.R. Banegas, M.J. García, J.L. Gutiérrez-Fisac, E. López, F. Rodríguez-Artalejo.
Asociación de la enfermedad cardiovascular con el sobrepeso y la obesidad en España.
Med Clin (Barc), 118 (2002), pp. 616-618
[17.]
J. Stevens, J. Cai, E.R. Pamuk, D.F. Williamson, M.J. Thun, J.L. Wood.
The effect of age on the association between body-mass index and mortality.
N Engl J Med, 338 (1998), pp. 1-7
[18.]
E. Alegría, A. Cordero, A. Grima, J.A. Casasnovas, M. Laclaustra, E. Luengo, et al.
Prevalencia de síndrome metabólico en población laboral española: Registro MESYAS.
Rev Esp Cardiol, 58 (2005), pp. 797-806
[19.]
S. Verma, S.H. Li, C.H. Wang, P.W. Fedak, R.K. Li, R.D. Weisel, et al.
Resistin promotes endotelial cell activation. Further evidence of adipokine-endothelial interaction.
Circulation, 108 (2003), pp. 736-740
[20.]
Y. Iwashima, T. Katsyuya, K. Ishikawa, N. Ouchi, M. Ohishi, K. Sugimoto, et al.
Hypoadiponectinemia is an independent risk factor for hypertension.
Hypertension, 43 (2004), pp. 1318-1323
[21.]
N. Eikelis, M. Schlaich, A. Aggarwal, D. Kaye, M. Esler.
Interactions between leptin and the human sympathetic nervous system.
Hypertension, 41 (2003), pp. 1072-1079
[22.]
J.E. Hall.
The kidney, hypertension and obesity.
Hypertension, 41 (2003), pp. 625-633
[23.]
J. Chen, P. Muntner, L.L. Hamm, D.W. Jones, V. Batuman, V. Fonseca, et al.
The metabolic syndrome and chronic kidney disease in US adults.
Ann Intern Med, 140 (2004), pp. 167-174
[24.]
Cordero A, Laclaustra M, León M, Casasnovas JA, Grima A, Nájar M, et al. Factores de riesgo cardiovascular y síndrome metabólico asociados con la disfunción renal subclínica. Med Clin (Barc). En prensa. 2005.
[25.]
A. Scuteri, A.S. Najjar, D.C. Muller, R. Andres, H. Hougaku, E.J. Metter, et al.
Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness.
Am J Coll Cardiol, 43 (2004), pp. 1388-1395
[26.]
P. Verdecchia, G. Reboldi, F. Angeli, C. Borgioni, R. Gattobigio, L. Filippucci, et al.
Adverse prognostic significance of new diabetes in treated hypertensive subjects.
Hypertension, 43 (2004), pp. 963-969
[27.]
M.P. Reilly, D.J. Rader.
The metabolic syndrome: more than the sum of it's parts?.
Circulation, 108 (2003), pp. 1546-1551
[28.]
E.E. Álvarez, L. Ribas, L. Serra.
Prevalencia del síndrome metabólico en la población de la Comunidad Canaria.
Med Clin (Barc), 120 (2003), pp. 172-174
[29.]
J.A. Gimeno, J.M. Lou, E. Molinero, B. Poned, D.P. Portilla.
Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2.
Rev Esp Cardiol, 57 (2004), pp. 507-513
[30.]
Y. Wang, Q.J. Wang.
The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee guidelines.
Arch Intern Med, 164 (2004), pp. 2126-2134
[31.]
K.J. Greenland, J.B. Croft, G.A. Mensah.
Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000.
Arch Intern Med, 164 (2004), pp. 2113-2118
[32.]
M. Kanauchi, K. Kanauchi, T. Hashimoto, Y. Saito.
Metabolic syndrome and new category «pre-hypertension» in a Japanese population.
Curr Med Res Opin, 20 (2004), pp. 1365-1370
[33.]
Cordero A, Laclaustra M, León M, Grima A, Casasnovas JA, Luengo E, et al. Prehypertension is associated ith insulin resistance state and not with an initial renal function impairment: a MESYAS registry substudy. AJH. En prensa. 2005
[34.]
T.J. Orchard, M. Temerosa, R. Goldberg, S. Haffner, R. Ratner, S. Marcovina, et al.
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial.
Ann Intern Med, 142 (2005), pp. 611-619
[35.]
I. Bautista-Castaño, J. Molina-Cabrillana, J.A. Montoya-Alonso, L. Serra-Majem.
Factores de riesgo cardiovascular en el sobrepeso y la obesidad. Variaciones tras tratamiento de pérdida ponderal.
Med Clin (Barc), 121 (2003), pp. 485-491
[36.]
B.M. Brenner, M.E. Cooper, D. De Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, et al.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med, 345 (2001), pp. 861-869
[37.]
H.L. Hillege, W.H. Van Gilst, D.J. Van Veldhuisen, G. Navis, D.E. Grobee, P.A. De Graeff, et al.
Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibitor: the CATS randomized trial.
Eur Heart J, 24 (2003), pp. 412-420
[38.]
M.P. Tokmakova, H. Skali, S. Kenchiah, E. Braunwald, J.L. Rouleau, M. Packer, et al.
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction. The Survival And Ventricular Enlargement (SAVE) study.
Circulation, 110 (2004), pp. 1667-1673
[39.]
J.R. González-Juanatey, P. Mazón, F. Soria, V. Barrios, L. Rodríguez, V. Bertomeu.
Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial.
Rev Esp Cardiol, 56 (2003), pp. 487-497
[40.]
G.L. Bakris, V. Fonseca, R.E. Katholi, J.B. McGill, F.H. Messerli, R.A. Phillips, et al.
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled study.
JAMA, 292 (2004), pp. 2227-2236
[41.]
C.J. Pepine, E.M. Handberg, R.M. Cooper-Dehoff, R.G. Marks, P. Kowey, F.H. Messerli, et al.
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (INVEST): a randomized controlled trial.
JAMA, 290 (2003), pp. 2805-2816
[42.]
P.S. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet, 361 (2004), pp. 1149-1158
[43.]
H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial.
[44.]
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial.
JAMA, 290 (2003), pp. 486-494
[45.]
T.D. Wang, W.J. Chen, J.W. Lin, M.F. Chen, Y.T. Lee.
Effects of rosiglitazone on endothelial function, c-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.
Am J Cardiol, 93 (2004), pp. 362-365
[46.]
D. Choi, S.K. Kim, S.H. Choi, Y.G. Ko, C.W. Ahn, Y. Jang, et al.
Preventive effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
Diabetes Care, 27 (2004), pp. 2654-2660
Copyright © 2005. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?